Figure 5.

The prophylactic and therapeutic efficacy of MR14 against Omicron BA.2 in vivo

(A) Neutralization of pseudotyped virus by homo-trimeric and IgM versions of nanobodies post-aerosolization in Vero cells; n = 3 per nanobody concentration point. Experiments were independently repeated twice with similar results, and one representative curve is displayed.

(B) The percentage of remaining nanobodies in the lungs of BALB/c mice post-aerosolization (n = 3).

(C) The percentage of remaining nanobodies in the blood after a single 20 mg/kg dose in BALB/c mice via intraperitoneal injection (n = 3).

(D) Lung viral sgRNA_E loads in the BA.2 variant-infected mice with the indicated treatments; n = 5 biologically independent mice in all groups. The solid lines indicate the median lung viral sgRNA_E loads. Ordinary one-way ANOVA with Sidak’s multiple comparisons was used in the statistical analyses.

(E) Representative histopathology of lung tissues in BA.2-infected mice (3 dpi). The images and areas of interest (black boxes) are magnified 10× and 40×, respectively.